1. Home
  2. NIE vs VIR Comparison

NIE vs VIR Comparison

Compare NIE & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$25.42

Market Cap

718.5M

Sector

Finance

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$6.10

Market Cap

825.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIE
VIR
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
718.5M
825.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NIE
VIR
Price
$25.42
$6.10
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$25.73
AVG Volume (30 Days)
70.5K
2.1M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
9.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,860,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$48.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.61
$4.16
52 Week High
$22.47
$14.45

Technical Indicators

Market Signals
Indicator
NIE
VIR
Relative Strength Index (RSI) 55.37 49.41
Support Level $25.10 $5.73
Resistance Level $25.07 $6.11
Average True Range (ATR) 0.27 0.39
MACD 0.03 -0.08
Stochastic Oscillator 77.61 28.57

Price Performance

Historical Comparison
NIE
VIR

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: